FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3013768877> ?p ?o ?g. }

• W3013768877 endingPage "113937" @default.
• W3013768877 startingPage "113937" @default.
• W3013768877 abstract "Latent HIV reservoirs are the main obstacle to eradicate HIV infection. One strategy proposes to eliminate these viral reservoirs by pharmacologically reactivating the latently infected T cells. We show here that a 4-deoxyphorbol ester derivative isolated from Euphorbia amygdaloides ssp. semiperfoliata, 4β-dPE A, reactivates HIV-1 from latency and could potentially contribute to decrease the viral reservoir. 4β-dPE A shows two effects in the HIV replication cycle, infection inhibition and HIV transactivation, similarly to other phorboids PKC agonists such PMA and prostratin and to other diterpene esters such SJ23B. Our data suggest 4β-dPE A is non-tumorigenic, unlike the related compound PMA. As the compounds are highly similar, the lack of tumorigenicity by 4β-dPE A could be due to the lack of a long side lipophilic chain that is present in PMA. 4β-dPE activates HIV transcription at nanomolar concentrations, lower than the concentration needed by other latency reversing agents (LRAs) such as prostratin and similar to bryostatin. PKCθ/MEK activation is required for the transcriptional activity, and thus, anti-latency activity of 4β-dPE A. However, CD4, CXCR4 and CCR5 receptors down-regulation effect seems to be independent of PCK/MEK, suggesting the existence of at least two different targets for 4β-dPE A. Furthermore, NF-κb transcription factor is involved in 4β-dPE HIV reactivation, as previously shown for other PKCs agonists. We also studied the effects of 4β-dPE A in combination with other LRAs. When 4β-dPE A was combined with another PKC agonists such as prostratin an antagonic effect was achieved, while, when combined with an HDAC inhibitor such as vorinostat, a strong synergistic effect was obtained. Interestingly, the latency reversing effect of the combination was synergistically diminishing the EC50 value but also increasing the efficacy showed by the drugs alone. In addition, combinations of 4β-dPE A with antiretroviral drugs as CCR5 antagonist, NRTIs, NNRTIs and PIs, showed a consistent synergistic effect, suggesting that the combination would not interefer with antiretroviral therapy (ART). Finally, 4β-dPE A induced latent HIV reactivation in CD4 + T cells of infected patients under ART at similar levels than the tumorigenic phorbol derivative PMA, showing a clear reactivation effect. In summary, we describe here the mechanism of action of a new potent deoxyphorbol derivative as a latency reversing agent candidate to decrease the size of HIV reservoirs." @default.
• W3013768877 created "2020-04-03" @default.
• W3013768877 creator A5014067137 @default.
• W3013768877 creator A5018299115 @default.
• W3013768877 creator A5026190126 @default.
• W3013768877 creator A5038227667 @default.
• W3013768877 creator A5043749537 @default.
• W3013768877 creator A5046130287 @default.
• W3013768877 creator A5046939099 @default.
• W3013768877 creator A5052923211 @default.
• W3013768877 creator A5062549658 @default.
• W3013768877 creator A5068814687 @default.
• W3013768877 creator A5075847331 @default.
• W3013768877 creator A5081815233 @default.
• W3013768877 creator A5090888719 @default.
• W3013768877 date "2020-07-01" @default.
• W3013768877 modified "2023-10-12" @default.
• W3013768877 title "4-Deoxyphorbol inhibits HIV-1 infection in synergism with antiretroviral drugs and reactivates viral reservoirs through PKC/MEK activation synergizing with vorinostat" @default.
• W3013768877 cites W1876390333 @default.
• W3013768877 cites W1969075395 @default.
• W3013768877 cites W1970662179 @default.
• W3013768877 cites W1982884889 @default.
• W3013768877 cites W1998241838 @default.
• W3013768877 cites W2005312568 @default.
• W3013768877 cites W2011208161 @default.
• W3013768877 cites W2024643457 @default.
• W3013768877 cites W2034302618 @default.
• W3013768877 cites W2037524921 @default.
• W3013768877 cites W2062148688 @default.
• W3013768877 cites W2066704458 @default.
• W3013768877 cites W2066848476 @default.
• W3013768877 cites W2090238266 @default.
• W3013768877 cites W2096939661 @default.
• W3013768877 cites W2098194107 @default.
• W3013768877 cites W2117693290 @default.
• W3013768877 cites W2160634299 @default.
• W3013768877 cites W2166237809 @default.
• W3013768877 cites W2203560898 @default.
• W3013768877 cites W2263928028 @default.
• W3013768877 cites W2340444741 @default.
• W3013768877 cites W2341924879 @default.
• W3013768877 cites W2345789047 @default.
• W3013768877 cites W2365689470 @default.
• W3013768877 cites W2396421546 @default.
• W3013768877 cites W2417209002 @default.
• W3013768877 cites W2470126287 @default.
• W3013768877 cites W2560275317 @default.
• W3013768877 cites W2736822140 @default.
• W3013768877 cites W2756289771 @default.
• W3013768877 cites W277041599 @default.
• W3013768877 cites W2782696110 @default.
• W3013768877 cites W2804663340 @default.
• W3013768877 cites W2895919826 @default.
• W3013768877 cites W2906115228 @default.
• W3013768877 cites W2913427365 @default.
• W3013768877 cites W2981803065 @default.
• W3013768877 cites W3003221987 @default.
• W3013768877 doi "https://doi.org/10.1016/j.bcp.2020.113937" @default.
• W3013768877 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/32224142" @default.
• W3013768877 hasPublicationYear "2020" @default.
• W3013768877 type Work @default.
• W3013768877 sameAs 3013768877 @default.
• W3013768877 citedByCount "9" @default.
• W3013768877 countsByYear W30137688772021 @default.
• W3013768877 countsByYear W30137688772022 @default.
• W3013768877 countsByYear W30137688772023 @default.
• W3013768877 crossrefType "journal-article" @default.
• W3013768877 hasAuthorship W3013768877A5014067137 @default.
• W3013768877 hasAuthorship W3013768877A5018299115 @default.
• W3013768877 hasAuthorship W3013768877A5026190126 @default.
• W3013768877 hasAuthorship W3013768877A5038227667 @default.
• W3013768877 hasAuthorship W3013768877A5043749537 @default.
• W3013768877 hasAuthorship W3013768877A5046130287 @default.
• W3013768877 hasAuthorship W3013768877A5046939099 @default.
• W3013768877 hasAuthorship W3013768877A5052923211 @default.
• W3013768877 hasAuthorship W3013768877A5062549658 @default.
• W3013768877 hasAuthorship W3013768877A5068814687 @default.
• W3013768877 hasAuthorship W3013768877A5075847331 @default.
• W3013768877 hasAuthorship W3013768877A5081815233 @default.
• W3013768877 hasAuthorship W3013768877A5090888719 @default.
• W3013768877 hasBestOaLocation W30137688772 @default.
• W3013768877 hasConcept C104317684 @default.
• W3013768877 hasConcept C1292079 @default.
• W3013768877 hasConcept C159047783 @default.
• W3013768877 hasConcept C185592680 @default.
• W3013768877 hasConcept C55493867 @default.
• W3013768877 hasConcept C86339819 @default.
• W3013768877 hasConcept C86803240 @default.
• W3013768877 hasConcept C98274493 @default.
• W3013768877 hasConceptScore W3013768877C104317684 @default.
• W3013768877 hasConceptScore W3013768877C1292079 @default.
• W3013768877 hasConceptScore W3013768877C159047783 @default.
• W3013768877 hasConceptScore W3013768877C185592680 @default.
• W3013768877 hasConceptScore W3013768877C55493867 @default.
• W3013768877 hasConceptScore W3013768877C86339819 @default.
• W3013768877 hasConceptScore W3013768877C86803240 @default.
• W3013768877 hasConceptScore W3013768877C98274493 @default.
• W3013768877 hasFunder F4320313831 @default.

• next